A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT02963766

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02963766
  • EudraCT 2016-000361-22
Other papers using this trial's data
  • Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes The New England journal of medicine, 2022-08-04 DOI, PubMed 35658022

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, France, Germany, Hungary, India, Mexico, Puerto Rico, Saudi Arabia, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02963766. Randomized; double masking; primary purpose treatment. Start 2016-12-29 (actual); primary completion 2021-06-12 (actual). Results posted on 2022-07-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Acronym
AWARD-PEDS
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02963766
Content hash
213a01c83f025b24307a51c62490ce1865152f0cd2099b2fa06be13fb313441e